Journal of Clinical Oncology, Vol 25, No 33 (November 20), 2007: pp. 5180-5186
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.12.0782
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer
Stephen A. Cannistra,
Ursula A. Matulonis,
Richard T. Penson,
Julie Hambleton,
Jakob Dupont,
Howard Mackey,
Jeffrey Douglas,
Robert A. Burger,
Deborah Armstrong,
Robert Wenham,
William McGuire
From the Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, MA; Genentech Inc, South San Francisco; University of California at Irvine, Orange, CA; The Johns Hopkins Kimmel Cancer Center; Franklin Square Hospital, Baltimore, MD; and Moffitt Cancer Center, Tampa, FL
Address reprint requests to Stephen A. Cannistra, MD, Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215; e-mail: scannist{at}bidmc.harvard.edu
Purpose We evaluated the efficacy and safety of bevacizumab in patients with platinum-resistant epithelial ovarian carcinoma (EOC) or peritoneal serous carcinoma (PSC) who had experienced disease progression during, or within 3 months of discontinuing, topotecan or liposomal doxorubicin.
Patients and Methods No more than three prior treatment regimens were allowed. Patients received single-agent bevacizumab 15 mg/kg intravenously every 3 weeks. Response was assessed by computed tomography (CT) scan every 6 weeks using Response Evaluation Criteria in Solid Tumors (RECIST).
Results Of 44 patients treated, 83.7% were primarily platinum resistant, 59.1% had received liposomal doxorubicin, 25% topotecan, 15.9% both agents, and 47.7% had received three prior chemotherapy regimens. A median of five (range, two to 16) bevacizumab doses were administered. Partial responses were observed in seven patients (15.9%). Median progression-free survival was 4.4 months (95% CI, 3.1 to 5.5 months), with a median survival duration of 10.7 months at study termination. Bevacizumab-associated grade 3 to 4 events included hypertension (9.1%), proteinuria (15.9%), bleeding (2.3%), and wound-healing complications (2.3%). The incidence of GI perforation (GIP; 11.4%) was higher than reported in bevacizumab trials of other tumor types. GIP occurred in 23.8% of patients receiving three prior chemotherapy regimens, compared with 0% of patients receiving two prior chemotherapy regimens (P < .01). A trend toward higher risk of GIP was observed for patients with bowel wall thickening or bowel obstruction on CT scan. Arterial thromboembolic events occurred in three patients (6.8%). Three deaths were related to bevacizumab treatment.
Conclusion Bevacizumab has single-agent activity in patients with platinum-resistant EOC or PSC. A higher than expected incidence of GIP was noted in these heavily pretreated patients.
Supported by Genentech Inc.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
Related Article
- Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Robert A. Burger, Michael W. Sill, Bradley J. Monk, Benjamin E. Greer, and Joel I. Sorosky
JCO 2007 25: 5165-5171
[Abstract]
[Full Text]
Related Editorial
- Bevacizumab for the Treatment of Epithelial Ovarian Cancer: Will This Be Its Finest Hour?
Stanley B. Kaye
JCO 2007 25: 5150-5152
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
A. du Bois, J. Huober, P. Stopfer, J. Pfisterer, P. Wimberger, S. Loibl, V. L. Reichardt, and P. Harter
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
Ann. Onc.,
November 4, 2009;
(2009)
mdp506v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Banerjee and M. Gore
The Future of Targeted Therapies in Ovarian Cancer
Oncologist,
July 1, 2009;
14(7):
706 - 716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. ITANI, K. HOSOKAWA, K. ITO, S. TAKEUCHI, T. TABATA, H. TSUBAMOTO, H. FUJITA, M. AKIYAMA, and S. ADACHI
A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer
Anticancer Res,
May 1, 2009;
29(5):
1521 - 1526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mabuchi, Y. Terai, K. Morishige, A. Tanabe-Kimura, H. Sasaki, M. Kanemura, S. Tsunetoh, Y. Tanaka, M. Sakata, R. A. Burger, et al.
Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
Clin. Cancer Res.,
December 1, 2008;
14(23):
7781 - 7789.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Korzets, U. Gafter, A. Chagnac, B. Zingerman, V. Morduchovitz, and Y. Ori
Thalidomide: a treatment option for bleeding GI angiodysplasias in dialysed patients
NDT Plus,
October 1, 2008;
1(5):
354 - 356.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Nachman and S. Rafii
Platelets, Petechiae, and Preservation of the Vascular Wall
N. Engl. J. Med.,
September 18, 2008;
359(12):
1261 - 1270.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Cannistra
Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies
J. Clin. Oncol.,
August 1, 2008;
26(22):
3665 - 3667.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Azad, E. M. Posadas, V. E. Kwitkowski, S. M. Steinberg, L. Jain, C. M. Annunziata, L. Minasian, G. Sarosy, H. L. Kotz, A. Premkumar, et al.
Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
J. Clin. Oncol.,
August 1, 2008;
26(22):
3709 - 3714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Belotti, C. Calcagno, A. Garofalo, D. Caronia, E. Riccardi, R. Giavazzi, and G. Taraboletti
Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion
Mol. Cancer Res.,
April 1, 2008;
6(4):
525 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Levine, B. M. Ronnett, P. F. Mansfield, and C. Eng
Overview of Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
ASCO Educational Book,
January 1, 2008;
2008(1):
153 - 159.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. B. Kaye
Bevacizumab for the Treatment of Epithelial Ovarian Cancer: Will This Be Its Finest Hour?
J. Clin. Oncol.,
November 20, 2007;
25(33):
5150 - 5152.
[Full Text]
[PDF]
|
 |
|
|